Inventor · disambiguated record
Hanqing Dong
Also filed as: DONG HANQING
52 granted patents·37 pending applications·288 citations·filing 2005–2025
98Inventor score
Top patents by PatentIndex Score
89 records- 0198US11883393B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2020·Granted Jan 30, 2024·5 cites·4 claims
- 0298US11236051B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2020·Granted Feb 1, 2022·9 cites·3 claims
- 0398US11104666B2Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2020·Granted Aug 31, 2021·18 cites·15 claims
- 0498US10899742B1Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2020·Granted Jan 26, 2021·18 cites·25 claims
- 0598US10647698B2Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS INC·Filed 2017·Granted May 12, 2020·31 cites·6 claims
- 0697US11597720B2Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2020·Granted Mar 7, 2023·4 cites·48 claims
- 0797US10730870B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS INC·Filed 2016·Granted Aug 4, 2020·25 cites·22 claims
- 0896US10772962B2Compounds and methods for the targeted degradation of bromodomain-containing proteinsARVINAS INC·Filed 2016·Granted Sep 15, 2020·15 cites·23 claims
- 0995US12077509B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2023·Granted Sep 3, 2024·1 cites·4 claims
- 1095US11981683B2Indazole based compounds and associated methods of useARVINAS OPERATIONS INC·Filed 2022·Granted May 14, 2024·5 cites·2 claims
- 1195US10723717B2Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptidesARVINAS INC·Filed 2017·Granted Jul 28, 2020·16 cites·44 claims
- 1292US11964945B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2020·Granted Apr 23, 2024·2 cites·26 claims
- 1392US11173211B2Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptidesARVINAS OPERATIONS INC·Filed 2019·Granted Nov 16, 2021·6 cites·25 claims
- 1492US10071164B2Estrogen-related receptor alpha based protac compounds and associated methods of useUNIV YALE·Filed 2015·Granted Sep 11, 2018·8 cites·9 claims
- 1592US7465726B2Substituted pyrrolo[2.3-B]pyridinesOSI PHARM INC·Filed 2005·Granted Dec 16, 2008·35 cites·14 claims
- 1691US11384063B2Modulators of estrogen receptor proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2020·Granted Jul 12, 2022·2 cites·8 claims
- 1791US7923555B2Fused bicyclic mTor inhibitorsOSI PHARM INC·Filed 2008·Granted Apr 12, 2011·15 cites·2 claims
- 1890US2025320195A1Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 1989US11161841B2Modulators of proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2019·Granted Nov 2, 2021·3 cites·22 claims
- 2089US7820662B26,6-bicyclic ring substituted heterobicyclic protein kinase inhibitorsOSI PHARM INC·Filed 2008·Granted Oct 26, 2010·12 cites·19 claims
- 2189US2025034096A1Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 2288US11352351B2Compounds and methods for the targeted degradation of androgen receptorARVINAS INC·Filed 2016·Granted Jun 7, 2022·4 cites·16 claims
- 2387US12043612B2Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the sameARVINAS OPERATIONS INC·Filed 2021·Granted Jul 23, 2024·3 cites·12 claims
- 2487US10604506B2Modulators of estrogen receptor proteolysis and associated methods of useARVINAS INC·Filed 2018·Granted Mar 31, 2020·3 cites·20 claims
- 2587US8101613B26,6-bicyclic ring substituted heterobicyclic protein kinase inhibitorsARNOLD LEE D·Filed 2009·Granted Jan 24, 2012·10 cites·15 claims
- 2685US12427144B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2023·Granted Sep 30, 2025·0 cites·16 claims
- 2785US11707452B2Modulators of alpha-synuclein proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2019·Granted Jul 25, 2023·2 cites·19 claims
- 2885US11427548B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2019·Granted Aug 30, 2022·2 cites·15 claims
- 2985US8399433B2Amino pyrimidine anticancer compoundsAPPARI RAMA DEVI·Filed 2010·Granted Mar 19, 2013·16 cites·25 claims
- 3085US2025228944A1Compounds and methods for the targeted degradation of bromodomain-containing proteinsARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 3184US11512083B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS OPERATIONS INC·Filed 2020·Granted Nov 29, 2022·1 cites·17 claims
- 3284US2024076281A1Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2022·Application pending·0 cites
- 3383US11458123B2Tau-protein targeting PROTACs and associated methods of useARVINAS INC·Filed 2017·Granted Oct 4, 2022·2 cites·16 claims
- 3482US9096624B2Amino pyrimidine anticancer compoundsOSI PHARMACEUTICALS LLC·Filed 2013·Granted Aug 4, 2015·6 cites·7 claims
- 3582US2025223265A1Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 3681US10865202B2Indole derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2019·Granted Dec 15, 2020·1 cites·20 claims
- 3780US12171831B2Compounds and methods for the targeted degradation of bromodomain- containing proteinsARVINAS OPERATIONS INC·Filed 2022·Granted Dec 24, 2024·0 cites·14 claims
- 3879US12441708B2Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2022·Granted Oct 14, 2025·0 cites·20 claims
- 3979US12239711B2Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2022·Granted Mar 4, 2025·0 cites·1 claims
- 4079US2024382599A1Egfr proteolysis targeting chimeric molecules and associated methods of useARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 4178US12264157B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS OPERATIONS INC·Filed 2022·Granted Apr 1, 2025·0 cites·24 claims
- 4278US12172981B2Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2021·Granted Dec 24, 2024·0 cites·18 claims
- 4378US2025313547A1Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2025·Application pending·0 cites
- 4477US2025360219A1Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2025·Application pending·0 cites
- 4576US2024059686A1Compounds and methods for the targeted degradation of the androgen receptorARVINAS OPERATIONS INC·Filed 2022·Application pending·0 cites
- 4674US7439256B2(Arylamidoaryl) cyanoguanidine compoundsCASTELHANO ARLINDO·Filed 2005·Granted Oct 21, 2008·5 cites·8 claims
- 4774US2024299366A1Imide-based modulators of proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2023·Application pending·0 cites
- 4874US2021040044A1Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2020·Application pending·0 cites
- 4973US12275716B2Modulators of estrogen receptor proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2022·Granted Apr 15, 2025·0 cites·16 claims
- 5072US7388012B2(Hydrazido)(amino)thiophene compoundsOSI PHARM INC·Filed 2005·Granted Jun 17, 2008·1 cites·14 claims
Showing the top 50 of 89 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Hanqing Dong files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →